Celltrion
068270.KS
#748
Rank
C$37.64 B
Marketcap
$181.76
Share price
0.72%
Change (1 day)
10.05%
Change (1 year)
Celltrion is a Korean pharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion.

P/E ratio for Celltrion (068270.KS)

P/E ratio as of November 2024 (TTM): 43.8

According to Celltrion 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 43.7866. At the end of 2022 the company had a P/E ratio of 42.1.

P/E ratio history for Celltrion from 2007 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202242.1-11.55%
202147.6-49.67%
202094.517.79%
201980.3-27.67%
201811147.95%
201775.0-9%
201682.425.66%
201565.678.62%
201436.7-3.29%
201338.0126.06%
201216.8-28.83%
201123.6-31.39%
201034.431.39%
200926.2-123.93%
2008-109-1596.8%
20077.31

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.